Randomized Trial of Atopaxar in the Treatment of Patients With Coronary Artery Disease | Zendy

Stephen D. Wiviott | Zendy; Marcus Flather | Zendy; Michelle L. O’Donoghue | Zendy; Shinya Goto | Zendy; Desmond J. Fitzgerald | Zendy; Fernando Cura | Zendy; Philip E. Aylward | Zendy; Victor Guetta | Zendy; Dariusz Dudek | Zendy; Charles F. Contant | Zendy; Dominick J. Angiolillo | Zendy; Deepak L. Bhatt | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Randomized Trial of Atopaxar in the Treatment of Patients With Coronary Artery Disease

Author(s) -

Stephen D. Wiviott,

Marcus Flather,

Michelle L. O’Donoghue,

Shinya Goto,

Desmond J. Fitzgerald,

Fernando Cura,

Philip E. Aylward,

Victor Guetta,

Dariusz Dudek,

Charles F. Contant,

Dominick J. Angiolillo,

Deepak L. Bhatt

Publication year - 2011

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.110.001404

Subject(s) - medicine , randomized controlled trial , coronary artery disease , cardiology , disease

Thrombin is a key mediator of platelet activation. Atopaxar is a reversible protease-activated receptor-1 antagonist that interferes with thrombin-mediated platelet effects. The phase II Lessons From Antagonizing the Cellular Effect of Thrombin-Coronary Artery Disease (LANCELOT-CAD) trial examined the safety and tolerability of prolonged therapy with atopaxar in subjects with CAD.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research